Fortrea Q2 Revenue Beats by $30M, Full-Year Guidance Raised
FTRE has more than doubled off its 52-week low of $5.265 on elevated volume (2.2× avg).
Summary
Fortrea delivered a strong Q2, with revenue of $678.2M beating consensus by nearly $31M and adjusted EBITDA of $58.7M topping estimates by $10M. The company raised its full-year 2026 revenue guidance to $2.62B-$2.69B and adjusted EBITDA to $205M-$220M, signaling confidence in sustained demand. This follows a CFO transition in late June and a recent court order sidelining the newly appointed CFO, adding leadership uncertainty. The book-to-bill ratio above 1.0x for the fourth straight quarter underscores commercial momentum. With the stock trading near its 52-week high, the raised outlook could drive further upside if execution continues.
At the time of this announcement, FTRE was trading at $20.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $5.27 to $21.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.